Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...